Xenofon Baraliakos, ACR 2022: Comparison of BASDAI vs. ASDAS in evaluating symptoms of axial involvement in psoriatic arthritis

In this post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies, which investigated guselkumab in axial psoriatic arthritis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) were compared in evaluating symptoms of axial involvement in psoriatic arthritis. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany) to discuss the advantages and disadvantages of both scores, and the details and findings of the post-hoc analysis.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract ‘Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies‘ (Abstract number: 1037) was presented at the ACR Convergence, November 10–14, 2022.

Questions

1. What are the limitations of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in assessing axial disease in patients with psoriatic arthritis? (0:26)
2. What are the potential advantages of the Ankylosing Spondylitis Disease Activity Score (ASDAS)? (2:08)
3. Could you give us a brief overview of your post-hoc analysis of the DISCOVER-1 and 2 studies? (3:42)
4. How did the BASDAI and ASDAS perform in this study? (5:53)

Disclosures: Xenofon Baraliakos discloses consulting for: Abbvie, Amgen, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, and UCB; receiving grant/research support from: Abbvie, Lilly, and MSD; serving on advisory boards for: Abbvie, Amgen, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, and UCB; receiving honoraria/honorarium from: Abbvie, Amgen, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, and UCB; and participating in speaker’s bureaus with: Abbvie, Amgen, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, and UCB.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ACR Convergence 2022.